Visual hallucinations are associated with lower αbungarotoxin binding in dementia with Lewy bodies

Patients with dementia with Lewy bodies (DLB) commonly experience psychotic symptoms, most notably visual hallucinations. Previously, it has been shown that visual hallucinations in DLB are associated with reduced cortical choline acetyltransferase activity, a marker of cholinergic innervation, but not with predominantly postsynaptic muscarinic M1 receptor binding. In the present investigation, nicotinic acetylcholine receptor (nAChR) levels in the temporal cortex (Brodmann's areas [BA] 20 and 36) were measured in a group of 24 prospectively assessed DLB patients; comparisons were made between groups with or without visual and auditory hallucinations and delusional misidentification. Visual hallucinations and delusional misidentification were associated with lower [(125)I]alpha bungarotoxin binding in areas 36 and 20 (P<.05), but not with changes in [(3)H]epibatidine binding. There were no significant associations with auditory hallucinations. [(3)H]epibatidine, but not [(125)I]alpha bungarotoxin, binding for all DLB cases was reduced compared to controls (P<.001). Loss of cortical alpha 7 nicotinic receptors may contribute to hallucinations and delusional misidentification in DLB, with implications for treatment and understanding the mechanisms of psychotic symptoms in dementia.

[1]  L. Schneider,et al.  Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer's disease. , 1994, Archives of neurology.

[2]  I. McKeith,et al.  Neuroleptic sensitivity to risperidone in Lewy body dementia , 1995, The Lancet.

[3]  A. Nordberg,et al.  Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain. , 1999, Brain research. Molecular brain research.

[4]  E. Perry,et al.  Nigrostriatal dopaminergic activities in dementia with lewy bodies in relation to neuroleptic sensitivity: comparisons with parkinson’s disease , 1998, Biological Psychiatry.

[5]  K Ugurbil,et al.  Activation of visuomotor systems during visually guided movements: a functional MRI study. , 1998, Journal of magnetic resonance.

[6]  M. Hutchinson,et al.  Cholinesterase inhibition in Parkinson's disease. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[7]  D. Bass,et al.  Symptoms of mental impairment among elderly adults and their effects on family caregivers. , 1986, Journal of gerontology.

[8]  E. Perry,et al.  Delusions associated with elevated muscarinic binding in dementia with Lewy bodies , 2000, Annals of neurology.

[9]  Hans Förstl,et al.  Psychotic features and the course of Alzheimer's disease: relationship to cognitive, electroencephalographic and computerized tomography findings , 1993, Acta psychiatrica Scandinavica.

[10]  Agneta Nordberg,et al.  Neuronal nicotinic receptors in the human brain , 2000, Progress in Neurobiology.

[11]  D. Bennett,et al.  Hallucinations and associated factors in Alzheimer's disease. , 1991, The Journal of neuropsychiatry and clinical neurosciences.

[12]  H. Haeske-Dewick Hallucinations in Parkinson's disease: Characteristics and associated clinical features , 1995 .

[13]  Abraham Weizman,et al.  Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease. , 1996, Advances in neurology.

[14]  L Kruglyak,et al.  Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Moossy,et al.  Neuropathologic and neurochemical correlates of psychosis in primary dementia. , 1991, Archives of neurology.

[16]  Wayne C. Drevets,et al.  Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type , 1989, Biological Psychiatry.

[17]  R. H. Perry,et al.  Acetylcholine and Hallucinations - Disease-Related Compared to Drug-Induced Alterations in Human Consciousness , 1995, Brain and Cognition.

[18]  G. Wilcock,et al.  The prevalence and phenomenology of psychotic symptoms in dementia sufferers , 1995 .

[19]  J. Copeland,et al.  Computerized diagnosis from a standardized history schedule: A preliminary communication about the organic section of the HAS–AGECAT system , 1992 .

[20]  D. Jeste,et al.  A Study of Delusions in a Large Cohort of Alzheimer's Disease Patients. , 1994, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[21]  J. Changeux,et al.  Identification of Four Classes of Brain Nicotinic Receptors Using β2 Mutant Mice , 1998, The Journal of Neuroscience.

[22]  E. Perry,et al.  Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson’s disease and Alzheimer’s disease and in relation to neuroleptic medication , 2000, Neuroscience.

[23]  A. Kurz,et al.  DELUSIONS AND HALLUCINATIONS IN ALZHEIMER'S DISEASE: RESULTS FROM A TWO‐YEAR LONGITUDINAL STUDY , 1996 .

[24]  E. Perry,et al.  Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer's disease. , 1999, The American journal of psychiatry.

[25]  B. Gulanski,et al.  Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease , 1998, Neurology.

[26]  D. Benson,et al.  Dementia: A Clinical Approach , 1983 .

[27]  P. Riederer,et al.  Human post-mortem striatal α4β2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome , 2000, Neuroscience Letters.

[28]  A. Owen,et al.  Psychiatric, neurological and medical aspects of misidentification syndromes: a review of 260 cases , 1991, Psychological Medicine.

[29]  E. Perry,et al.  Neuroleptic sensitivity in patients with senile dementia of Lewy body type. , 1992, BMJ.

[30]  K. Marder,et al.  The Columbia University Scale for Psychopathology in Alzheimer's disease. , 1992, Archives of neurology.

[31]  G. Zubenko,et al.  Emergence of psychosis and depression in the longitudinal evaluation of Alzheimer's disease , 1991, Biological Psychiatry.

[32]  J. Grace,et al.  Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease , 1998, The Lancet.

[33]  K. Kosaka,et al.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB) , 1996, Neurology.

[34]  G. Stebbins,et al.  Intravenous levodopa in hallucinating Parkinson's disease patients , 1998, Neurology.

[35]  L. Thal,et al.  Nicotinic receptor losses in dementia with Lewy bodies: comparisons with Alzheimer’s disease , 2000, Neurobiology of Aging.

[36]  P. Ince,et al.  The UPDRS scale as a means of identifying extrapyramidal signs in patients suffering from dementia with Lewy bodies , 1997, Acta neurologica Scandinavica.

[37]  J. O'Brien,et al.  A Prospective Study of Psychotic Symptoms in Dementia Sufferers: Psychosis in Dementia , 1997, International Psychogeriatrics.

[38]  R. Kerwin,et al.  Neuronal Nicotinic Receptors in Dementia with Lewy Bodies and Schizophrenia , 1999, Journal of neurochemistry.

[39]  E. Perry,et al.  Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use , 1998, Neuroscience.

[40]  M. Skaff,et al.  Caregiving and the stress process: an overview of concepts and their measures. , 1990, The Gerontologist.

[41]  E. Perry,et al.  Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types , 1990, Journal of neural transmission. Parkinson's disease and dementia section.

[42]  Mrinalini Honavar,et al.  Lewy bodies and response to tacrine in Alzheimer's disease , 1994, The Lancet.

[43]  P V Rabins,et al.  The impact of dementia on the family. , 1982, JAMA.

[44]  R Freedman,et al.  Nicotinic receptor function in schizophrenia. , 1996, Schizophrenia bulletin.

[45]  Robert H. Perry,et al.  Senile dementia of Lewy body type A clinically and neuropathologically distinct form of Lewy body dementia in the elderly , 1990, Journal of the Neurological Sciences.

[46]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[47]  R. Howard,et al.  Donepezil for the treatment of psychosis in dementia with Lewy bodies , 2000, International journal of geriatric psychiatry.

[48]  K. Blennow,et al.  Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. , 1999, Neuroreport.

[49]  R. Freedman,et al.  Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia , 1995, Biological Psychiatry.

[50]  G A Chase,et al.  Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. , 1990, The American journal of psychiatry.

[51]  D. Irving,et al.  Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: Possible index of early neuropathology , 1995, Neuroscience.

[52]  K. Rockwood,et al.  Donepezil for Treatment of Dementia With Lewy Bodies: A Case Series of Nine Patients , 1998, International Psychogeriatrics.

[53]  F. Huppert,et al.  CAMDEX: A Standardised Instrument for the Diagnosis of Mental Disorder in the Elderly with Special Reference to the Early Detection of Dementia , 1986, British Journal of Psychiatry.

[54]  E. Perry,et al.  Evidence of a Monoaminergic‐Cholinergic Imbalance Related to Visual Hallucinations in Lewy Body Dementia , 1990, Journal of neurochemistry.

[55]  A. Burns,et al.  Psychiatric Phenomena in Alzheimer's Disease. I: Disorders of Thought Content , 1990, British Journal of Psychiatry.

[56]  P. Clarke The fall and rise of neuronal α-bungarotoxin binding proteins , 1992 .